SINOVAC Reports Unaudited First Half of 2026 Financial Results

About this update from Sinovac Biotech, Ltd.

BEIJING, August 17, 2026--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial results for the six months ended June 30, 2026 with the U.S. Securities and Exchange Commission. An electronic copy of the financial results can be accessed at the Company's website at www.sinovac.com and at the SEC's website www.sec.gov. First Half of 2026 Financial Summary Mr. Weidong Yin, CEO of SINOVAC, commented, "In the first half of 2026, SINOVAC delivered steady revenue growth, driven primarily by the sustained expansion of overseas business. Overseas revenue rose 82.3% and accounted for 45.2% of total revenue, demonstrating the continued optimization of our revenue mix under the Company's globalization strategy. The rabies vaccine for human use (PVRV-SF) received marketing approval from the National Medical Products Administration (NMPA) in August 2026. Developed from the outset with global markets in mind, the vaccine represents an important addition to our commercial portfolio, and we plan to pursue WHO prequalification (WHO PQ) to broaden access to it worldwide. In terms of research and development (R&D), the New Drug Application (NDA) for our bivalent enterovirus vaccine for the prevention of hand, foot and mouth disease (HFMD2) is under official review, and five additional vaccine candidates are currently undergoing Phase III clinical trials. We remain committed to accelerating the global development and commercialization of our innovative pipeline and further strengthening the foundation for sustainable long-term growth." Strong Overseas Growth and Domestic Resilience In the first half of 2026, the Company's total sales increased by 12.9% compared with the same period in 2025, reaching $147.1 million. Overseas revenue increased by 82.3% over the same period to $66.5 million, accounting for approximately 45.2% of total sales and serving as the primary driver of the Company's revenue growth. In the Chinese Mainland market, the continued decline in births dampened demand for certain products. As the Company advances its core R&D pipeline, the commercialization of innovative products is expected to become an increasingly important growth driver for its domestic business. The varicella vaccine and poliomyelitis vaccine, sabin...

View stock analysis, news, and events for Sinovac Biotech, Ltd.